Affordable Access

deepdyve-link
Publisher Website

Sirolimus: Efficacy and Complications in Children With Hyperinsulinemic Hypoglycemia: A 5-Year Follow-Up Study

Authors
  • Maria, Güemes1, 2
  • Antonia, Dastamani1
  • Michael, Ashworth3
  • Kate, Morgan1
  • Sian, Ellard4
  • Sarah, Flanagan E4
  • Mehul, Dattani1, 2
  • Pratik, Shah1, 2
  • 1 Endocrinology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
  • 2 Section of Genetics and Epigenetics in Health and Disease, Genetics and Genomic Medicine Programme, University College London Great Ormond Street Hospital Institute of Child Health, London, United Kingdom
  • 3 Histopathology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
  • 4 Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, United Kingdom
Type
Published Article
Journal
Journal of the Endocrine Society
Publisher
The Endocrine Society
Publication Date
Feb 07, 2019
Volume
3
Issue
4
Pages
699–713
Identifiers
DOI: 10.1210/js.2018-00417
PMID: 30882046
PMCID: PMC6411415
Source
PubMed Central
Keywords
License
Unknown

Abstract

Introduction Sirolimus, a mammalian target of rapamycin inhibitor, has been used in congenital hyperinsulinism (CHI) unresponsive to diazoxide and octreotide. Reported response to sirolimus is variable, with high incidence of adverse effects. To the best of our knowledge, we report the largest group of CHI patients treated with sirolimus followed for the longest period to date. Methods Retrospective study of CHI patients treated with sirolimus in a tertiary service and review of the 15 publications reporting CHI patients treated with mammalian target of rapamycin inhibitors. Comparison was made between the findings of this study with those previously published. Results Twenty-two CHI patients treated with sirolimus were included in this study. Twenty showed partial response, one showed complete response, and one was unresponsive. Five of the partially/fully responsive patients had compound heterozygous ABCC8 mutations and five had heterozygous ABCC8 mutations. A total of 86.4% (19/22) developed complications, with infection being the most frequent (17/22), of which 11 were of bacterial etiology, followed by persistent diarrhea (3/22) and hyperglycemia (2/22). Seventeen patients stopped sirolimus: 13 from infections; 2 from hyperglycemia; and 2 from alternative treatment (lanreotide) response. Compared with data previously published, our study identified a higher number of partially sirolimus-responsive CHI cases, although the high rate of complications while on this medication limited its potential usefulness. Conclusion Sirolimus candidates must be carefully selected given its frequent and potentially life-threatening side effects. Its use as a short-term, last-resort therapy until normoglycemia is achieved with other agents such as lanreotide could avoid pancreatectomy. Further studies evaluating the use of sirolimus in patients with CHI are required.

Report this publication

Statistics

Seen <100 times